News | March 03, 2022
Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The first wave of shipments includes several countries, such as Germany, France and Austria
Subscribe To Our Newsletter & Stay Updated
